Clinical trials: Estrogen
Breast Cancer, Cancer of the Breast
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.
- Conditions
- Breast Cancer, Cancer of the Breast, Neoplasms, Breast
- Trial name
- NCT00661531
- Testing
- Estrace, Anastrozole
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Georgetown University
Breast Cancer
Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography
The purpose of this study is to evaluate the uptake of a radioactive tracer 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione (FFNP) uptake, which binds to breast cancer progesterone receptors…
- Trial name
- NCT02455453
- Testing
- 18F-FFNP, CTI/Siemens Biograph 40 PET/CT Scanner, Estradiol
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Washington University School of Medicine
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
This phase I/II trial studies the side effects and best dose of hydroxychloroquine when given together with palbociclib and letrozole before surgery in treating patients with estrogen receptor positive, HER2 negative breast…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03774472
- Testing
- Hydroxychloroquine, Letrozole, Palbociclib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT00407888
- Testing
- doxorubicin hydrochloride, cyclophosphamide, filgrastim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
HIV, Prophylaxis
Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW
This is a research study to determine the best way to dose Truvada®, an oral medication licensed to be taken as Pre-Exposure Prophylaxis (PrEP) to prevent HIV infection, in transgender women who are also taking feminizing…
- Conditions
- HIV, Prophylaxis, Transgender
- Trial name
- NCT04760691
- Testing
- Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Estrogen Receptor-positive Breast Cancer, Gastrinoma
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
This phase II trial studies how well real-time pharmacokinetic therapeutic drug monitoring works in preventing stomatitis from developing in patients with hormone receptor positive breast cancer, pancreatic neuroendocrine tumors…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Gastrinoma, Glucagonoma, HER2-negative Breast Cancer
- Trial name
- NCT02273752
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Arthralgia, Breast Cancer
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer.
- Conditions
- Arthralgia, Breast Cancer, Pain
- Trial name
- NCT01385137
- Testing
- omega-3 fatty acid
- Where
- 292 sites in United States
- Volunteers
- 262 people
- Sponsor
- SWOG Cancer Research Network
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
This randomized phase II trial studies how well carboplatin and combination chemotherapy with or without veliparib works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01818063
- Testing
- Paclitaxel, Carboplatin, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Genitourinary Syndrome of Menopause (GSM)
A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause
Non-hormonal alternatives for the treatment of genitourinary syndrome of menopause (GSM) are needed. In this proposed trial, patients who are diagnosed with GSM will be randomized to receive either a hyaluronic acid (HLA) vaginal…
- Trial name
- NCT04544475
- Testing
- Revaree, Estrace
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Estrogen Deficiency, Cardiovascular Disease (CVD)
Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
The purpose of this study is to determine whether young women with functional hypothalamic amenorrhea (premenopausal HypoE) is associated with risk factors for pre-clinical cardiovascular disease (CVD).
- Conditions
- Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
- Trial name
- NCT03018366
- Testing
- 17beta Estradiol, Progesterone
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Estrogen Receptor Negative, HER2/Neu Negative
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT02445391
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 1,024 sites in United States, South Africa
- Volunteers
- 415 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Early Breast Cancer (Phase 2), Advanced Breast Cancer (Phase 1b)
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer
PF-04691502 is an inhibitor of PI3K and mTOR kinase. Published data support the hypothesis that a PI3K/mTOR antagonist in combination with letrozole might mitigate the intrinsic or acquired resistance to hormonal therapy and…
- Trial name
- NCT01430585
- Testing
- PF-04691502, PF-04691502 in combination with Letrozole, Letrozole
- Where
- 5 sites in Belgium, Italy and 2 more
- Volunteers
- 14 people
- Sponsor
- Pfizer
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
This phase II trial studies how well pegylated liposomal doxorubicin hydrochloride and carboplatin followed by surgery and paclitaxel work in treating patients with stage II-III breast cancer that does not have estrogen…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT02315196
- Testing
- pegylated liposomal doxorubicin hydrochloride, epirubicin hydrochloride, carboplatin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- TEXT (NCT00066703)
- Testing
- exemestane, tamoxifen, triptorelin
- Where
- 228 sites in United States, Australia and 15 more
- Volunteers
- 2,672 people
- Sponsor
- ETOP IBCSG Partners Foundation
Recurrent Urinary Tract Infection, Urinary Tract Infections
Preventing Recurrent UTI With Vaginal Estrogen
Among postmenopausal women who suffer from recurrent urinary tract infections (UTI), vaginal estrogen therapy prevents UTI recurrences for 50% of sufferers.
- Conditions
- Recurrent Urinary Tract Infection, Urinary Tract Infections, Cystitis Recurrent
- Trial name
- PRUVE (NCT05551949)
- Testing
- Vaginal estradiol tablets
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Johns Hopkins University
Urinary Tract Infections
Nutraceutical Efficacy for rUTI
This is a study designed to evaluate the efficacy of a nutraceutical as a non-antibiotic treatment to prevent recurrent urinary tract infections in women that have completed menopause and are on vaginal estrogen therapy.
- Trial name
- NCT03395288
- Testing
- D-Mannose
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Estrogen Receptor Negative, HER2/Neu Negative
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
This phase II trial studies how well tivantinib works in treating patients with recurrent or metastatic breast cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma
- Trial name
- NCT01575522
- Testing
- Laboratory Biomarker Analysis, Tivantinib
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Sexual Dysfunction, Physiological
Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
Vulvovaginal atrophy (VVA) is a condition that impacts up to 60% of the growing postmenopausal female population, and the most common symptom is dyspareunia.
- Trial name
- NCT03018106
- Testing
- Ospemifene, Vaginal conjugated estrogens
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS.
- Conditions
- Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT02774681
- Testing
- Cognitive Assessment, Palbociclib, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Traumatic Brain Injury
Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury
Each year in the United States alone, a third of a million persons are hospitalized for traumatic brain injury (TBI), of whom approximately 1/4 die. Most are less than 30 years of age.
- Trial name
- RESCUE-TBI (NCT00973674)
- Testing
- Premarin IV
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center